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Abstract
Objectives We aimed to evaluate optic chiasm (OC) measures as potential imaging marker for anterior optic pathway damage
assessment in the context of neuromyelitis optica spectrum disorders (NMOSD).
Materials andmethod This cross-sectional study included 39 patients exclusively with aquaporin 4-IgG seropositive NMOSD of
which 25 patients had a history of optic neuritis (NMOSD-ON) and 37 age- and sex-matched healthy controls (HC). OC heights,
width, and area weremeasured using standard 3DT1-weightedMRI. Sensitivity of these measures to detect neurodegeneration in
the anterior optic pathwaywas assessed in receiver operating characteristics analyses. Correlation coefficients were used to assess
associations with structural measures of the anterior optic pathway (optic nerve dimensions, retinal ganglion cell loss) and clinical
measures (visual function and disease duration).
Results OC heights and area were significantly smaller in NMOSD-ON compared to HC (NMOSD-ON vs. HC p < 0.0001). An
OC area smaller than 22.5 mm2 yielded a sensitivity of 0.92 and a specificity of 0.92 in separating chiasms of NMOSD-ON from
HC. OC area correlated well with structural and clinical measures in NMOSD-ON: optic nerve diameter (r = 0.4, p = 0.047),
peripapillary retinal nerve fiber layer thickness (r = 0.59, p = 0.003), global visual acuity (r = − 0.57, p = 0.013), and diseases
duration (r = − 0.5, p = 0.012).
Conclusion Our results suggest that OC measures are promising and easily accessible imaging markers for the assessment of
anterior optic pathway damage.
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Key Points
• Optic chiasm dimensions were smaller in neuromyelitis optica spectrum disorder patients compared to healthy controls.
• Optic chiasm dimensions are associated with retinal measures and visual dysfunction.
• The optic chiasmmight be used as an easily accessible imaging marker of neurodegeneration in the anterior optic pathway with
potential functional relevance.
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Abbreviations
AQP4-IgG Aquaporin 4-IgG
AUC Area under the curve
CI 95% confidence interval
CoV Coefficient of variation
EDSS Expanded Disability Status Scale
GCIPL Combined ganglion cell-inner
plexiform layer
HC Healthy controls
ICC Intraclass correlations
logMAR Logarithm of the minimum
angle of resolution
NMOSD Neuromyelitis optica spectrum disorders
NMOSD-ON Neuromyelitis optica patients with
history of optic neuritis
NMOSD-NON Neuromyelitis optica patients without
history of optic neuritis
OC Optic chiasm
OCT Optical coherence tomography
ON Optic neuritis
pRNFL Peripapillary retinal nerve fiber layer
ROC Receiver operating characteristics
Introduction
Neuromyelitis optic spectrum disorders (NMOSDs) are in-
flammatory autoimmune CNS diseases that preferentially tar-
get the optic nerves and are frequently associated with serum
autoantibodies to aquaporin-4 [1, 2]. Optic pathway degener-
ation following optic neuritis (ON) [3, 4] results in atrophy
involving the entire visual pathway [5–10]. At the optic chi-
asma (OC), fibers from the left and the right optic nerve merge
and form the site of highest axonal density. Direct damage or
other pathophysiological effects affecting the optic nerves
may accumulate in the OC, making it a promising target for
the assessment of anterior optic pathway damage.
Measures of optic pathway degeneration are an important
outcome measure of ON, since they are related to impaired
visual function and reduction of vision-related quality of life
[11–14]. Optic pathway dimensions as assessed by MRI have
been used as a surrogate marker of inflammatory damage and
atrophy of the optic nerve and anatomically connected tracts
[3, 4, 15–18]. It has been suggested that MRI is sensitive to
axonal loss as a cause of optic nerve atrophy [17–20]. Optical
coherence tomography (OCT) reveals damage to the retinal
axons and ganglion cells by means of measuring peripapillary
retinal nerve fiber layer (pRNFL) thickness and combined
ganglion cell-inner plexiform layer (GCIPL) volume. OCT
measures have been successfully used as surrogate markers
of optic nerve atrophy [16, 17, 19, 21–25], being associated to
MRI-detected macro- and microstructural optic pathway atro-
phy and visual function [16, 17, 20, 26–28].
AlthoughMRI is used as part of the routine clinical workup
of NMOSD patients [29, 30], no method to evaluate optic
pathway damage has been established. In addition to the ac-
cumulation of damage within the anterior optic pathway, the
OC appears particularly promising as a potential imaging
marker, since it would simplify evaluation by reducing the
region of interest from multiple structures to one. Only few
studies have focused on the assessment of physiologic OC
dimensions [31–33] and their changes in optic atrophy [18],
while quantitative correlation analysis to visual function and
optic pathway degeneration has not been performed.
The aim of this study was to assess whether neurodegener-
ative changes in the anterior optic pathway are detectable by
assessing OC measures. We hypothesized that the OC assess-
ment in standard 3D-T1w images is sensitive to anterior optic
pathway damage. To test this hypothesis, we used NMOSD as
amodel for optic pathway damage and compared different OC
measures (area, width, left, central, right, and total height)
between aquaporin 4-IgG (AQP4-IgG) seropositive
NMOSD patients with and without history of ON
(NMOSD-ON and NMOSD-NON) and healthy controls
(HC). In addition, we investigated the association of OC mea-
sures with optic nerve diameter, visual acuity, pRNFL thick-
ness, and GCIPL volume in NMOSD-ON.
Material and methods
Study population
Data of 78 NMOSD patients acquired from an ongoing lon-
gitudinal prospective observational cohort study at the
NeuroCure C l in i ca l Resea rch Cen te r , Cha r i t é -
Universitätsmedizin Berlin (recruited from May 2013 to
January 2018) were screened for eligibility. All patients (i)
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were 18 years or older and (ii) had a diagnosis of AQP4-IgG
seropositive NMOSD according to the current panel criteria
[29] and (iii) either had a last ON attack at least 5 months prior
to MRI or had no history of ON. AQP4-IgG status was deter-
mined by a cell-based assay (Euroimmun, Lübeck, Germany).
Patients with AQP4-IgG seronegative (n = 25) antibody sta-
tus, unknown antibody status and/or incomplete clinical data
(n = 10), lacking MRI data (n = 3), or ON within 5 months
prior to MRI (n = 1) were excluded.
Thirty-nine patients exclusively with AQP4-IgG seroposi-
tive NMOSD and 37 age- and sex-matched HC subjects were
included in this study (Table 1). All HC subjects were 18 years
or older and had ophthalmologic testing and no history of
neurological or ophthalmological diseases.
This study was approved by the local ethics committee
(Ethikkommission der Charité–Universitätsmedizin Berlin;
EA1/131/09) and conducted according the declaration of
Helsinki and applicable German law. All participants gave
written informed consent.
MRI acquisition
MRI data were acquired on the same 3-T scanner
(MAGNETOM Trio, A Tim System, Siemens) at the Berlin
Center for Advanced Neuroimaging using a volumetric high-
resolution T1-weighted MPRAGE sequence (RT = 1900 ms,
TE = 3.03 ms, TI = 900 ms, FOV = 256 × 256 mm2, matrix
256 × 256, slice thickness 1 mm). OC measurements were
performed on reconstructed 3D MPRAGE MR images.
Optic chiasm measures
After training with a neuroradiologist with more than 8 years
of experience (M.S.), OC and optic nerve measurements were
performed by V.J. (radiology trainee), blinded to clinical data,
using a standardized protocol: First, the central point of the
OC was determined on all 3 planes. The axes of the planes
were reoriented to the course of the optic pathway, so that they
were perpendicular to the orientation of the individual OC in
the central point. On the individually reoriented transversal
plane, OC area, heights, and width were measured. Optic
nerve diameters were measured in the cisternal segment
7 mm anterior to the previously defined central point of the
OC perpendicular to the optic nerve course (Figs. 1 and 2). All
measurements were performed using region-of-interest soft-
w a r e f r o m H o r o s , v e r s i o n 3 . 3 . 2 ( h t t p s : / /
www.horosproject.org). Width was defined as the diameter
along the adjusted frontal axis. Heights were measured per-
pendicularly to that diameter: central height at the middle, the
lateral heights at the maximal diameter left and right to the
center. For interrater reliability analysis, J.V. and M.C.
(trainee) measured OC dimensions within 10 randomly select-
ed HC and intraclass correlations (ICC) were calculated.
Clinical assessment
Neurological disability was on the Expanded Disability Status
Scale (EDSS), including the visual functional system score
according to the Neurostatus definitions [34]. Raters were
Table 1 Demographics and clinical characteristics
HC NMOSD-
NON
NMOSD-ON p
Number 37 14 25 –
Age, years (mean, SD) 47.8 (12.6) 53.8 (12.5) 48.09 (14.9) 0.33
Sex (F/M) (% female) 30/7 (81%) 14/0 (100%) 21/4 (84%) 0.22
Disease duration, years (median, range) – – 7.1 (3–34.1)
Number of ON (median, range) – – 2 (1–12) –
Time since first ON, years (median, range) – – 6.9 (3.4–32.2) –
Time since last ON, years (median, range) – – 4.9 (0.5–13.2) –
ON involvement, bilateral/unilateral – – 11/14
(8 right/6 left)
–
Optic nerve diameter, mm (mean, SD) 8.37 (0.50) 8.13 (0.90) 7.06 (1.23) < 0.001
pRNFL, μm (mean, SD) 91.99 (15.10) 97.96 (10.13) 67.57 (17.92) < 0.001
GCIPL mm3 (mean, SD) 1.83 (0.28) 1.88 (0.14) 1.49 (0.25) < 0.001
Visual acuity, logMAR (mean, SD) − 0.01 (0.21) −0.15 (0.21) 0.30 (0.63) 0.04
Visual Functional System Score (median, range) – 0 (0–2) 1 (0–6) < 0.001
EDSS (median, range) – 3 (1–7) 4 (0–6.5) 0.71
p values are groupwise comparisons.HC = healthy controls;NMOSD-ON = neuromyelitis optica patients with history of optic neuritis;NMOSD-NON =
neuromyelitis optica patients without history of optic neuritis; ON = optic neuritis; pRNFL = peripapillary retinal nerve fiber layer; GCIPL = combined
ganglion cell-inner plexiform layer; logMAR = logarithm of the minimum angle of resolution; EDSS = Expanded Disability Status Scale
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under the supervision of board-certified neurologists. The
global neurological examination also included assessment of
ON history using clinical criteria. Visual acuity was tested
monocular ly under phototopic condi t ions us ing
retroilluminated Early Treatment in Diabetes Retinopathy
Study charts at a 4-m distance. The logarithm of the minimum
angle of resolution (logMAR) served as a measure of visual
function. Visual acuity data was included only from patients
where best correction was used (n = 30).
Optical coherence tomography measures
All OCT data were acquired on a spectral domain OCT device
(Spectralis, Heidelberg Engineering) with automated real-time
function. No pupil dilatation was used. We report the OCT
acquisition settings and scanning protocol according to the
APOSTEL recommendations [35]: The pRNFL thickness
was measured using 3.4-mm ring scans around the optic nerve
head (12°, 1536 A-scans, 9 ≤ART ≤ 100). The GCIPL vol-
ume was measured using a 6-mm diameter cylinder around
the fovea from a macular volume scan (25°×30°, 61 vertical
B-scans, 768 A-scans per B-scan, ART = 15). Segmentation
of the pRNFL and the intraretinal layers in the macular scan
was performed semi-automatically using software provided
by the optical coherence tomography manufacturer (Eye
Explorer 1.9.10.0 with viewing module 6.0.9.0; Heidelberg
Engineering). Quality was evaluated according to the
OSCAR-IB criteria [36, 37].
Two patients did not have OCT data. Eight eyes from six
NMOSD-ON had to be excluded due to incidental findings or
quality reasons. Only the macular scan from two additional
NMOSD-ON eyes was excluded due to quality reasons.
Statistics
Proportional group differences were tested with χ2 test for sex
and with ANOVA test for age. For comparison of ordinal and
continuous measurements, groupwise comparison was per-
formed using Kruskal-Wallis and ANOVA tests, respectively.
Group comparison of OC dimensions was corrected for mul-
tiple comparison using the Holm-Bonferroni method. The var-
iations of the individual metrics were compared within the HC
Fig. 1 Optic chiasm measurement. Panels a, b, and c illustrate how axes were adjusted perpendicularly to the orientation of the OC in the center point.
Panel d shows a sample OC measurement (a = right, b = central, c = left height, d = area, e = width)
Fig. 2 Optic nerve measurement. Panels a, b, and c illustrate how axes were adjusted perpendicularly to the orientation of the optic nerve
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group using a coefficient of variation (CoV) computed accord-
ing to
CoV ¼ standard deviation of the individual metric
mean of the individual metric
and served as an indicator of variation in the individual OC
measures. Sensitivity to optic nerve atrophy of individual OC
measures was evaluated with receiver operating characteristic
(ROC) analysis, including area under the curve (AUC) com-
parison using DeLong method [38]. Association analysis of
individual OCmeasures with the T2 lesion load, the SIENAX
V-scaling [39] factor for head size and gender as potential
influencing factors, mean optic nerve diameter, mean
pRNFL thickness, mean GCIPL volume, visual function
(mean logMAR), and disease duration was performed with
the Pearson correlation test, association with the number of
ON attacks with the Spearman test.
Statistical analyses were performed using R software, ver-
sion 3.5.1. (http://www.r-project.org/) with the tidyverse [40],
ggpubr [41], and pROC packages [42]. Statistical significance
was set at a p value < 0.05.
Results
Demographics
Table 1 shows the demographic and clinical characteristics of
the cohort. No significant differences of sex distribution, age,
and physical disability were found between groups. Optic
nerve diameters were different in NMOSD-ON compared to
HC (p < 0.0001), NMOSD-ON compared to NMOSD-NON
(p < 0.01), but not in NMOSD-NON compared to HC
(p > 0.05).
Group comparison and receiver operating
characteristics
Figure 3 shows the OC of NMOSD-ON, NMOSD-NON, and
HC to illustrate the reduction of OC dimensions in NMOSD.
All OCmeasures except widthwere significantly smaller in
all group comparisons (NMOSD-ON vs. HC: p < 0.0001;
NMOSD-NON vs. HC: p < 0.01; and NMO-ON vs. NMO-
NON: p < 0.03), as shown in Table 2 and Fig. 4. When
correcting for multiple comparisons (corrected p = 0.003), this
remained significant for all measures for HC vs. NMOSD-
ON, for all measures except left height for HC vs. NMOSD-
NON and for area for NMOSD-NON vs. NMOSD-ON.
OC measures were not associated with the T2 lesion load
(r = − 0.35, p > 0.09), the number of ON attacks (r = − 0.31,
p > 0.13), the number of ON attacks per side (r = − 0.09,
p > 0.13), the SIENAX V-scaling factor, or gender (r < 0.08,
p > 0.23). Thus, no correction for head size or sex was
performed.
A ROC analysis was conducted to test the ability of the OC
to predict the presence of damage in the anterior optic path-
way, namely to differentiate between groups. OC area and OC
heights have comparable AUC values for each group
(NMOSD-ON vs. HC: AUC > 0.92; NMOSD-NON vs. HC:
AUC > 0.74; NMO-ON vs. NMO-NON: AUC > 0.71),
whereas width has lower AUC values, as shown in Table 3
and Fig. 5. AUC comparison using DeLong method and var-
iation comparison using the CoVof the best performing mea-
sures revealed no significant difference. An OC area smaller
than 22.5 mm2 yielded a sensitivity of 0.92 and a specificity of
0.92 in separating chiasms of NMOSD-ON from HC.
Associations with structural and clinical measures
Table 4 summarizes the association analysis within the
NMOSD-ON group. Higher OC measures were associated
with bigger optic nerve diameter, better visual acuity, and
better OCT measures. This was most prominent for OC area:
Higher values significantly correlated with bigger optic nerve
diameter (r = 0.4, p = 0.047), better logMAR (r = − 0.57,
p = 0.013), thicker pRNFL (r = 0.59, p = 0.003), bigger
GCIPL (r = 0.55, p = 0.007), and shorter disease duration
(r = − 0.5, p = 0.012). Within OC heights, only central height
was significantly associated with GCIPL (r = 0.46, p = 0.028).
Discussion
We evaluated OC measures as imaging marker of anterior
optic pathway damage. We demonstrated significant group
differences between NMOSD patients and HC and strong as-
sociations of OC measures with structural and clinical mea-
sures. Our data show that OC assessment in standard 3D-T1w
images is sensitive to anterior optic pathway damage. Hence,
OC measures are easily accessible and sensitive markers of
anterior optic pathway damage.
OC dimension values for HC presented in our study are
similar to recently published data [33]. A previous study by
Wagner et al [31], however, reported slightly higher OCwidth
and area values. This study excluded OC height due to a high
degree of variance. Notably, unlike our study,Wagner et al did
not account for the transverse course of the optic pathway and
did not define precise measure locations. Thus, the coronal
plane would be at varying angles (not perpendicular) to the
course of the optic pathway at which OC assessment results in
higher values and variance. Furthermore, our study employed
a higher resolution MRI sequence, which may have an impact
on values and variance.
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OC heights and area showed differences between all
groups. This is in line with earlier investigations suggesting
that optic nerve dimensions discriminate ON patients from
controls [16]. OC assessment, as suggested in our study, only
requires a standard and broadly available MRI sequence (3D
T1-weighted MPRAGE) and assesses a rather fixed structure
less vulnerable to motion artifacts compared to the previously
used orbital optic nerves [3, 4, 16, 17]. Note that in this study
optic nerve diameters were measured in the cisternal segment
7 mm anterior to the OC, since contrast heterogeneity and
motion artifacts in the orbital part rendered orbital assessment
difficult in 25% of the patients. The observation that smaller
OC dimensions were also found in NMOSD-NON (compared
to HC and NMOSD-ON) supports microstructural changes in
the optic pathway independent of ON [26], which have been
described in NMOSD [5, 27, 43, 44]. In concordance with a
study by Harrigan et al [16], the optic nerve diameter was
smaller in patients with a history of ON compared to HC but
not in patients without ON. Although this should not be
overstated in consideration of the small NMOSD-NON sam-
ple size, this might indicate that microstructural changes inde-
pendent of ON, including anterograde degeneration
Table 2 Optic chiasm measures
Measure HC NMOSD-
NON
NMOSD-
ON
HC vs. NMOSD-
NON
HC vs. NMOSD-
ON
NMOSD-NON vs. NMOSD-
ON
CoV ICC
Left height (CI, mm) 2.77
(0.35)
2.34
(0.53)
1.94
(0.48)
t = 2.77
p = 0.01
t = 7.49
p < 0.0001
t = 2.36
p = 0.03
0.12 0.71
Central height (CI,
mm)
1.93
(0.32)
1.55
(0.39)
1.22
(0.32)
t = 3.27
p < 0.001
t = 8.63
p < 0.0001
t = 2.70
p = 0.013
0.16 0.51
Right height (CI, mm) 2.65
(0.36)
2.20
(0.46)
1.79
(0.43)
t = 3.31
p = 0.003
t = 8.23
p < 0.0001
t = 2.79
p = 0.008
0.14 0.77
Width (CI, mm) 12.23
(1.15)
12.17
(1.05)
11.43
(1.87)
t = 0.17
p = 0.56
t = 1.91
p = 0.059
t = 1.59
p = 0.18
0.09 0.95
Area (CI, mm2) 27.07
(3.50)
22.26
(4.65)
16.89
(4.44)
t = 3.51
p = 0.003
t = 9.61
p < 0.0001
t = 3.51
p = 0.001
0.13 0.89
Total height (CI, mm) 7.35
(0.90)
6.09
(1.33)
4.94
(1.14)
t = 3.27
p = 0.003
t = 8.86
p < 0.0001
t = 2.73
p = 0.009
0.12 0.76
Shown are means of OC measures. p and t-values are derived from t tests. Corrected p = 0.003. CI = 95% confidence interval; HC = healthy controls;
NMOSD-ON = neuromyelitis optica patients with history of optic neuritis; NMOSD-NON = neuromyelitis optica patients without history of optic
neuritis; CoV = coefficient of variation; ICC = intraclass correlations
Fig. 3 Difference in optic chiasm dimensions. Shown are OCs of NMOSD-ON (a, b), NMOSD-NON (c, d), and HC (e, f)
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originating from anterior optic pathway damage but also ret-
rograde degeneration originating from posterior optic pathway
damage, might accumulate in the OC.
The AUC values obtained from ROC analyses for OC area
and heights indicate that OCmeasures are sensitive to anterior
optic pathway damage. On the descriptive level, OC left
height shows slightly poorer ROC performance than right.
This might rather be caused by an asymmetric severity of
atrophy predominantly affecting fibers contributing to the
right side of the OC (8 ON right vs. 6 ON left), of handedness
Fig. 4 Optic chiasmmeasures. Group differences in optic chiasm heights,
width, and area between neuromyelitis optica spectrum disorders patients
with optic neuritis (NMOSD-ON), without optic neuritis (NMOSD-
NON), and healthy controls (HC). ns: p > 0.05, * p ≤ 0.05, ** p ≤ 0.01,
*** p ≤ 0.001, ****p ≤ 0.0001
Table 3 Receiver operating characteristics analysis
HC vs. NMOSD-ON Area Width Left
Height
Central
Height
Right
Height
Total
Height
AUC 0.95 0.64 0.90 0.95 0.92 0.94
95% CI 0.91–1.00 0.49–0.79 0.81–0.98 0.89–1.00 0.85–1.00 0.87–1.00
p value AUC comparison – < 0.01 0.02 0.78 0.16 0.40
HC vs. NMOSD-NON Area Width Left
Height
Central
Height
Right
Height
Total
Height
AUC 0.78 0.55 0.74 0.80 0.78 0.77
95% CI 0.57–0.92 0.38–0.73 0.52–0.88 0.59–0.95 0.62–0.94 0.60–0.94
p value AUC comparison – 0.08 0.31 0.49 0.93 0.77
NMOSD-ON vs. NMOSD-NON Area Width Left
Height
Central
Height
Right
Height
Total
Height
AUC 0.81 0.63 0.71 0.74 0.76 0.76
95% CI 0.69–0.95 0.46–0.80 0.54–0.89 0.59–0.90 0.57–0.90 0.60–0.92
p value AUC comparison – 0.08 0.06 0.19 0.29 0.14
Shown are area under the curve (AUC), 95% confidence interval (CI), and p value for AUC comparison using area as reference.HC = healthy controls;
NMOSD-ON = neuromyelitis optica patients with history of optic neuritis;NMOSD-NON = neuromyelitis optica patients without history of optic neuritis
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or other asymmetries present in our study, than by a different
sensitivity of the individual measure. This and the observation
that no association between ON attacks per side and OC
heights was found highlight the fact that OC assessment ac-
cumulates pathophysiologic processes of both sides and does
not provide information on the origin of the fibers.
The observed associations between higher OC area and
better visual acuity (r = − 0.57), thicker pRNFL (r = 0.53)
and bigger GCIPL (r = 0.55) in NMOSD are similar to the
associations reported on optic nerve dimensions (r = − 0.50,
r = 0.66, r = 0.59) in MS [17]. The degree of association be-
tween pRNFL and anterior optic pathway dimensions in MRI
Fig. 5 Receiver operating characteristic for optic chiasm measures. Each line represents one group differentiation: green lines HC vs. NMOSD-ON, red
lines HC vs. NMOSD-NON, blue lines NMOSD-ON vs. NMOSD-NON; ON= optic neuritis
Table 4 Associations of OC
measures and visual acuity, optic
nerve diameter and optical
coherence tomography measures
for NMOSD-ON patients
Mean Area Width Left
Height
Central
Height
Right
Height
Total
Height
Visual acuity (logMAR) r = − 0.57
p = 0.013
r = − 0.53
p = 0.023
r = − 0.05
p = 0.84
r = − 0.43
p = 0.079
r = − 0.21
p = 0.41
r = − 0.22
p = 0.39
Optic nerve diameter r = 0.4
p = 0.047
r = 0.75
p < 0.001
r = − 0.06
p = 0.78
r = − 0.09
p = 0.68
r = 0.09
p = 0.66
r = − 0.03
p = 0.87
pRNFL thickness r = 0.59
p = 0.003
r = 0.54
p = 0.008
r = 0.15
p = 0.49
r = 0.38
p = 0.07
r = 0.30
p = 0.16
r = 0.28
p = 0.19
GCIPL volume r = 0.55
p = 0.007
r = 0.33
p = 0.13
r = 0.19
p = 0.39
r = 0.46
p = 0.028
r = 0.34
p = 0.11
r = 0.33
p = 0.12
r values are Pearson’s correlation coefficients. NMOSD-ON = neuromyelitis optica patients with history of optic
neuritis; logMAR = logarithm of the minimum angle of resolution; pRNFL = peripapillary retinal nerve fiber layer;
GCIPL = combined ganglion cell-inner plexiform layer
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might be equally limited in NMOSD and MS, since axonal
loss is not the only substrate of neuronal atrophy and myelin
loss, gliosis, and changes in water content also contribute to
MRI-detected changes after ON [45]. Alongside findings sug-
gesting that axonal loss is a major substrate of MRI-detected
optic pathway atrophy after ON [17–20], the association be-
tween pRNFL (a surrogate for retinal axons) and OC mea-
sures implies that they are sensitive to atrophic changes of
the anterior optic pathway. The association of OC area with
visual function suggests a role for the OC as an imaging mark-
er of neurodegenerative damage in the optic pathway with
potential functional relevance.
Despite MRI’s broad availability, no standardized MRI
method for evaluation of optic pathway degeneration in stan-
dard scans is available. One major problem in optic nerve
assessment is defining standardized measurement locations
along the variable course of the nerve, which has high inter-
individual variability even in healthy populations [3, 4, 15,
17]. Several methods to measure optic nerve dimensions have
been put forward [16, 17, 32]. These methods typically in-
volve dedicated orbital MRI fat-saturated acquisition se-
quences along the axis of the optic nerve [3] additional to
the commonly acquired sequences and extend the scan time
for each patient. Others involve complex imaging post-
processing procedures [16] and, thus, may be difficult to im-
plement in the routine clinical workup. Moreover, motion ar-
tifacts from eye movements and contrast reduction in the pos-
terior region of the optic nerve, due to thinning of the CSF
filled sub-arachnoid space, render MRI-based optic nerve as-
sessment technically difficult [16]. This limits the accessibility
of optic nerve measurements using MRI in the clinical setting.
The OC is less vulnerable to motion artifacts and consis-
tently surrounded by CSF. It is less variable in morphology,
bigger in dimensions and, thus, a simple target for MR inves-
tigations. OC assessment, as suggested in our study, only re-
quires a broadly available MRI sequence (3D T1-weighted).
While it does not provide information on the origin of the
fibers and evaluation of focal optic nerve damage might better
be achieved by direct measurement at the sight of inflamma-
tion, it accumulates neurodegeneration from both sides of the
anterior optic pathway causing observable impairment. Thus,
it extends the amount of information from a single measure-
ment in the conventional and clinical standard scan, which can
be used for monitoring of disease progression or therapeutic
effectiveness.
Despite the low total number of subjects included in the
study owing to the low prevalence of the disease, a significant
difference in OCmeasures was shownwithin a relatively large
homogeneous cohort exclusively consisting of AQP4-IgG-
positive NMOSD patients. Separate gender analysis could
not be conducted due to the high proportion of female patients.
This is in line with the strong female preponderance in
NMOSD [46]. OC width was measured along straight lines,
which may not account for curved width. In future investiga-
tions, curved lines could be drawn; however, only few partic-
ipants showed recognizable deviation from straight lines and,
thus, we do not expect that this would drastically change the
presented results.
Our data provide a strong rationale for future, larger studies
on OC measures in ON, including in NMOSD patients with
acute ON, in which inflammation might result in an increase
in OC dimensions, as well as in patients with inflammatory
diseases such asMS andmyelin oligodendrocyte glycoprotein
antibody associated disease (MOGAD) [47]. Finally, studies
on the influence of susceptibility artifacts on scanners with
different field strength and resolution seem justified and the
application of advanced quantitative imaging methods such as
DTI could reveal insights into the relationship between ante-
rior and posterior optic pathway neurodegeneration.
Conclusion
Our study represents an initial and thorough assessment of OC
measures to evaluate optic pathway degeneration using stan-
dard MRI and shows that the OC area is suitable and reliable.
This simple method extends the amount of information that
can be obtained from conventional and clinically available
scans. Our results suggest that the OC might evolve into an
easily accessible imaging marker of neurodegeneration in the
anterior optic pathway with potential functional relevance.
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